FOLD News and Press, Amicus Therapeutics Inc. From 10/19/20

Amicus Therapeutics (FOLD), Plug Power (PLUG), and Fortress Transportation and Infrastructure Investors (FTAI) are trading at affordable prices even despite the market’s strong action off the March lows. These stocks have the necessary fundamentals to deliver solid returns while having...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this event. For further details see: Amicus Therapeutics (FOLD) Presents Interim Data for CLN6 Gene Therapy at Child Neurology Society Meet - Slideshow

CRANBURY, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program, AT-GTX-501. The results are featured in a virtual poster presentation at the Joint 16th International C...

Strong need for improved enzyme replacement therapies. Protalix's deliberately engineered ERT appears to fill this unmet need. Significant potential for share price appreciation. For further details see: Protalix Could Claim Substantial Global Market Share In Fabry Disea...

Amicus is making progress on all fronts and the progress is not fully reflected in the company's valuation. Galafold is on track to generate $500 million in global sales by 2023. The phase 3 trial of AT-GAA in Pompe disease patients is on track to report results in 1H 2021 and is ...

Amicus Therapeutics (FOLD) announced that the European Medicines Agency has granted priority medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease, also kno...

CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Medicines Agency (EMA) has grant...

Quick Take Taysha Gene Therapies ( TSHA ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing genetic therapy treatments for various neurodegenerative diseases and other disorders. TSHA is still at a precl...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this Read more ...

CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: Citi’s 15 th Annual BioP...